Mukesh Harisinghani, MD
Associate Professor of Radiology, Harvard Medical School Assistant Radiologist, Dept. of Abdominal Imaging Phone: 617-726-8396 Email: mharisinghani@mgh.harvard.edu Design and conduct clinical trials and provide an avenue for clinical testing of novel imaging agents developed at CMIR. Over the last several years we have conducted phase 1,2 and phase 3 clinical trials of monocrystalline iron oxides (1-2) for a number of applications. Current trials evaluate the efficacy of these agents to improve detection of subtle lymph node metastases in patients with prostate cancer (funded in part by RSNA) and renal cancer (funded in part by by SCBT). My primary clinical interests lie in abdominal and pelvic MR imaging Publications
2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1999 | 1998 | 1997
Paly JJ, Efstathiou JA, Hedgire SS, Chung PW, O'Malley M, Shah A, Bekelman JE, Harisinghani M, Shipley WU, Zietman AL, Beard C
Mapping patterns of nodal metastases in seminoma: Rethinking radiotherapy fields.
Rajesh A, Cloud G, Harisinghani MG
Improving the quality of manuscript reviews: impact of introducing a structured electronic template to submit reviews.
AJR Am J Roentgenol. 2013;200(1):20-3 - PMID: 23255737
Preston MA, Harisinghani MG, Mucci L, Witiuk K, Breau RH
Diagnostic tests in urology: magnetic resonance imaging (MRI) for the staging of prostate cancer.
BJU Int. 2013;111(3):514-7 - PMID: 23320634
Hedgire SS, Sainani NI, McDermott S, Hahn PF, Harisinghani MG
Mono-belly and beyond: spectrum of imaging manifestations of EBV infection in the abdomen.
Clin Imaging. 2013;:ePub - PMID: 23317894
4
Kaufman DS, Zietman AL, McDougal WS, Dahl DM, Harisinghani MG, Wu CL
Case records of the Massachusetts General Hospital. Case 9-2012. A 67-year-old man with a persistently elevated PSA level.
New Engl J Med. 2012;366(12):1143-50 - PMID: 22435374
Elmi A, Tabatabaei S, Talab SS, Hedgire SS, Cao K, Harisinghani M
Incidental findings at initial imaging workup of patients with prostate cancer: clinical significance and outcomes.
AJR Am J Roentgenol. 2012;199(6):1305-11 - PMID: 23169722
Hedgire SS, Pargaonkar VK, Elmi A, Harisinghani AM, Harisinghani MG
Pelvic nodal imaging.
Radiol Clin North Am. 2012;50(6):1111-25 - PMID: 23122041
McDermott S, Hedgire SS, Hahn PF, Mueller PR, Harisinghani MG
Image-Guided Biopsy of Suspicious Lymph Nodes in Patients with Known Primary Malignancies.
J Vasc Interv Radiol. 2012;23(3):371-6 - PMID: 22265244
Hartman RI, Chang CY, Wo JY, Eisenberg JD, Hong TS, Harisinghani MG, Gazelle GS, Pandharipande PV
Optimizing Adjuvant Treatment Decisions for Stage T2 Rectal Cancer Based on Mesorectal Node Size: A Decision Analysis.
Acad Radiol. 2012;20(1):79-89 - PMID: 22947271 - PMCID: PMC3525763
Hedgire SS, Elmi A, Nadkarni ND, Cao K, McDermott S, Harisinghani MG
Preoperative evaluation of perinephric fat invasion in patients with renal cell carcinoma: correlation with pathological findings.
Clin Imaging. 2012;37(1):91-6 - PMID: 23206613
Hedgire SS, Oei TN, McDermott S, Cao K, Patel M Z, Harisinghani MG
Multiparametric magnetic resonance imaging of prostate cancer.
Indian J Radiol Imaging. 2012;22(3):160-9 - PMID: 23599562 - PMCID: PMC3624737
Dejesus Allison SO, Javitt MC, Glanc P, Andreotti RF, Bennett GL, Brown DL, Dubinsky T, Harisinghani MG, Harris RD, Mitchell DG, Pandharipande PV, Pannu HK, Podrasky AE, Shipp TD, Siegel CL, Simpson L, Wong-You-Cheong JJ, Zelop CM
ACR Appropriateness Criteria® Multiple Gestations.
Ultrasound Q. 2012;28(2):149-155 - PMID: 22634795
8
Kaufman DS, Zietman AL, Dahl DM, Harisinghani MG, Wu CL
Case records of the Massachusetts General Hospital. Case 5-2011. A 65-year-old man with hematuria after treatment for prostate cancer.
New Engl J Med. 2011;364(7):667-75 - PMID: 21323545
Gee MS, Nimkin K, Hsu M, Israel EJ, Biller JA, Katz AJ, Mino-Kenudson M, Harisinghani MG
Prospective Evaluation of MR Enterography as the Primary Imaging Modality for Pediatric Crohn Disease Assessment.
AJR Am J Roentgenol. 2011;197(1):224-31 - PMID: 21701034
Larson AM, Hedgire SS, Deshpande V, Stemmer-Rachamimov AO, Harisinghani MG, Ferrone CR, Shah U, Thiele EA
Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex.
Clin Genet. 2011;82(6):558-63 - PMID: 22035404
Gee MS, Harisinghani MG
MRI in patients with inflammatory bowel disease.
J Magn Reson Imaging. 2011;33(3):527-534 - PMID: 21512607 - PMCID: PMC3078716
4
Gaglia JL, Guimaraes AR, Harisinghani M, Turvey SE, Jackson R, Benoist C, Mathis D, Weissleder R
Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients.
J Clin Invest. 2010;121(1):442-5 - PMID: 21123946 - PMCID: PMC3007157
Gultepe E, Reynoso FJ, Jhaveri A, Kulkarni P, Nagesha D, Ferris C, Harisinghani M, Campbell RB, Sridhar S
Monitoring of magnetic targeting to tumor vasculature through MRI and biodistribution.
Nanomedicine (Lond). 2010;5(8):1173-82 - PMID: 21039195
Pandharipande PV, Gervais DA, Hartman RI, Harisinghani MG, Feldman AS, Mueller PR, Gazelle GS
Renal Mass Biopsy to Guide Treatment Decisions for Small Incidental Renal Tumors: A Cost-effectiveness Analysis.
Radiology. 2010;256(3):836-46 - PMID: 20720070 - PMCID: PMC2923731
Uppot RN, Harisinghani MG, Gervais DA
Imaging-guided percutaneous renal biopsy: rationale and approach.
AJR Am J Roentgenol. 2010;194(6):1443-9 - PMID: 20489082
Cronin CG, Harisinghani MG, Catalano O, Blake MA
Multitechnique imaging findings of prolene plug hernia repair.
AJR Am J Roentgenol. 2010;195(3):701-6 - PMID: 20729449
Eisner BH, Kurtz MP, Harisinghani MG
Evolving Role of Magnetic Resonance Imaging in Renal Cancer Imaging.
J Endourol. 2010;24(5):707-11 - PMID: 20433369
de la Rosette J, Ahmed H, Barentsz J, Johansen TB, Brausi M, Emberton M, Frauscher F, Greene D, Harisinghani M, Haustermans K, Heidenreich A, Kovacs G, Mason M, Montironi R, Mouraviev V, de Reijke T, Taneja S, Thuroff S, Tombal B, Trachtenberg J, Wijkstra H, Polascik T
Focal therapy in prostate cancer-report from a consensus panel.
J Endourol. 2010;24(5):775-80 - PMID: 20477543
Islam T, Harisinghani MG
Prostate cancer imaging: what the next decade holds.
Expert Rev Med Devices. 2010;7(5):577-9 - PMID: 20822379
Sanghvi D, Harisinghani MG
Modalities in modern radiology: A synopsis.
J Postgrad Med. 2010;56(2):85-7 - PMID: 20622386
Ventura E, Islam T, Gee MS, Mahmood U, Braschi M, Harisinghani MG
Detection of nodal metastatic disease in patients with non-small cell lung cancer: comparison of positron emission tomography (PET), contrast-enhanced computed tomography (CT), and combined PET-CT.
Clin Imaging. 2010;34(1):20-28 - PMID: 20122515
Saokar A, Islam T, Jantsch M, Saksena MA, Hahn PF, Harisinghani MG
Detection of lymph nodes in pelvic malignancies with computed tomography and magnetic resonance imaging.
Clin Imaging. 2010;34(5):361-6 - PMID: 20813300
Saokar A, Gee MS, Islam T, Mueller PR, Harisinghani MG
Appearance of primary lymphoid malignancies on lymphotropic nanoparticle-enhanced magnetic resonance imaging using ferumoxtran-10.
Clin Imaging. 2010;34(6):448-52 - PMID: 21092874
Iyer VR, Hahn PF, Blaszkowsky LS, Thayer SP, Halpern EF, Harisinghani MG
Added Value of Selected Images Embedded Into Radiology Reports to Referring Clinicians.
J Am Coll Radiol. 2010;7(3):205-210 - PMID: 20193926 - PMCID: PMC3086392
13
Kaufman DS, McDougal WS, Harisinghani MG, Wu CL
Case records of the Massachusetts General Hospital. Case 30-2009. A 77-year-old man with recurrent transitional-cell carcinoma of the ureter.
New Engl J Med. 2009;361(13):1292-9 - PMID: 19776411
Macdonald SM, Harisinghani MG, Katkar A, Napolitano B, Wolfgang J, Taghian AG
Nanoparticle-Enhanced MRI to Evaluate Radiation Delivery to the Regional Lymphatics for Patients With Breast Cancer.
Int J Radiat Oncol Biol Phys. 2009;77(4):1098-104 - PMID: 19836160
Pandharipande PV, Mora JT, Uppot RN, Goehler A, Braschi M, Halpern EF, Gazelle GS, Harisinghani MG
Lymphotropic nanoparticle-enhanced MRI for independent prediction of lymph node malignancy: a logistic regression model.
AJR Am J Roentgenol. 2009;193(3):W230-7 - PMID: 19696264
Baier ND, Hahn PF, Gervais DA, Samir A, Halpern EF, Mueller PR, Harisinghani MG
Fine-needle aspiration biopsy of thyroid nodules: experience in a cohort of 944 patients.
AJR Am J Roentgenol. 2009;193(4):1175-9 - PMID: 19770344
Gee MS, Harisinghani MG, Tabatabaei S
Molecular imaging in urologic surgery.
Urol Clin N Am. 2009;36(2):125-32 - PMID: 19406314
Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU, Kaufman DS, Islam T, Guimaraes AR, Weissleder R, Harisinghani M
Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy.
Clin Imaging. 2009;33(4):301-5 - PMID: 19559353
Islam T, Harisinghani MG
Overview of nanoparticle use in cancer imaging.
Cancer Biomark. 2009;5:61-7 - PMID: 19414922
Harisinghani MG
Nanoparticle enhanced imaging.
8
Harisinghani M
Nanoparticle-enhanced MRI: are we there yet?
Lancet Oncol. 2008;9(9):814-815 - PMID: 18760237
Pandharipande PV, Harisinghani MG, Ozanne EM, Specht MC, Hur C, Lee JM, Gazelle GS
Staging MR Lymphangiography of the Axilla for Early Breast Cancer: Cost-Effectiveness Analysis.
AJR Am J Roentgenol. 2008;191:1308-19 - PMID: 18941062
Roedl JB, Harisinghani MG, Colen RR, Fischman AJ, Blake MA, Mathisen DJ, Mueller PR
Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
Ann Thorac Surg. 2008;86:1131-8 - PMID: 18805147
Feldman AS, McDougal WS, Harisinghani MG
The potential of nanoparticle-enhanced imaging.
Urol Oncol. 2008;26(1):65-73 - PMID: 18190834
Guimaraes AR, Tabatabei S, Dahl D, McDougal WS, Weissleder R, Harisinghani MG
Pilot Study Evaluating Use of Lymphotrophic Nanoparticle-Enhanced Magnetic Resonance Imaging for Assessing Lymph Nodes in Renal Cell Cancer.
Urology. 2008;71(4):708-12 - PMID: 18295316
Roedl JB, Blake MA, Holalkere NS, Mueller PR, Colen RR, Harisinghani MG
Lymph node staging in esophageal adenocarcinoma with PET-CT based on a visual analysis and based on metabolic parameters.
Abdom Imaging. 2008;34(5):610-7 - PMID: 18830663
Li CS, Harisinghani MG, Lin WC, Braschi M, Hahn PF, Mueller PR
Enhancement Characteristics of Ultrasmall Superparamagnetic Iron Oxide Particle Within the Prostate Gland in Patients With Primary Prostate Cancer.
J Comput Assist Tomogr. 2008;32:523-528 - PMID: 18664836
7
Harisinghani M, Ross R, Guimaraes A, Weissleder R
Utility of a New Bolus-Injectable Nanoparticle for Clinical Cancer Staging
Neoplasia. 2007;(9)12:1160-1165 - PMID: 18084623 - PMCID: PMC2134912
1
Harisinghani MG, Saksena MA, Hahn PF, King B, Kim J, Torabi MT, Weissleder R
Ferumoxtran-10-Enhanced MR Lymphangiography: Does Contrast-Enhanced Imaging Alone Suffice for Accurate Lymph Node Characterization?
AJR Am J Roentgenol. 2006;186(1):144-8 - PMID: 16357394
Saksena M, Harisinghani M, Hahn P, Kim J, Saokar A, King B, Weissleder R
Comparison of lymphotropic nanoparticle-enhanced MRI sequences in patients with various primary cancers.
AJR Am J Roentgenol. 2006;187(6):W582-8 - PMID: 17114509
Ross R, Harisinghani M
Prostate cancer imaging-what the urologic oncologist needs to know.
Radiol Clin North Am. 2006;44(5):711-22 - PMID: 17030222
Saksena MA, Saokar A, Harisinghani MG
Lymphotropic nanoparticle enhanced MR imaging (LNMRI) technique for lymph node imaging.
Eur J Radiol. 2006;58(3):367-74 - PMID: 16472955
Ross R, Harisinghani M
New clinical imaging modalities in prostate cancer.
Hematol Oncol Clin N. 2006;20(4):811-30 - PMID: 16861116
Saokar A, Braschi M, Harisinghani M
Lymphotrophic nanoparticle enhanced MR imaging (LNMRI) for lymph node imaging.
Abdom Imaging. 2006;31(6):660-7 - PMID: 16680506
6
Shih HA, Harisinghani M, Zietman AL, Wolfgang JA, Saksena M, Weissleder R.
Mapping of nodal disease in locally advanced prostate cancer: Rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy
Int J Radiat Oncol Biol Phys. 2005;63(4):1262-9 - PMID: 16253781
Harisinghani MG, Saksena M, Ross RW, Tabatabaei S, Dahl D, McDougal S, Weissleder R
A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation.
Urology. 2005;66(5):1066-71 - PMID: 16286125
2
Harisinghani MG, Weissleder R
Sensitive, noninvasive detection of lymph node metastases.
1
Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer
New Engl J Med. 2003;348:2491-9 - PMID: 12815134
1
Harisinghani MG, Barentsz JO, Hahn PF, Deserno W, de la Rosette J, Saini S, Marten K, Weissleder R
MR lymphangiography for detection of minimal nodal disease in patients with prostate cancer
Acad Radiol. 2002;9 Suppl 2:S312-3 - PMID: 12188258
1
Harisinghani MG, Jhaveri KS, Weissleder R, Schima W, Saini S, Hahn PF, Mueller PR
MRI contrast agents for evaluating focal hepatic lesions
Clin Radiol. 2001;56:714-25 - PMID: 11585393
Harisinghani MG, Saini S, Weissleder R, Rubin D, deLange E, Harms S, Weinreb J, Small W, Sukerkar A, Brown JJ, Zelch J, Lucas M, Morris M, Hahn PF
Splenic imaging with ultrasmall superparamagnetic iron oxide ferumoxtran-10 (AMI-7227): preliminary observations
J Comput Assist Tomogr. 2001;25:770-6 - PMID: 11584239
2
Harisinghani MG, Saini S, Weissleder R, Hahn PF, Yantiss RK, Tempany C, Wood BJ, Mueller PR
MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation
AJR Am J Roentgenol. 1999;172:1347-51 - PMID: 10227514
Schima W, Saini S, Petersein J, Weissleder R, Harisinghani M, Mayo-Smith W, Hahn PF
MR imaging of the liver with Gd-BOPTA: quantitative analysis of T1-weighted images at two different doses
J Magn Reson Imaging. 1999;10:80-3 - PMID: 10398981
2
Harisinghani MG, Saini S, Hahn PF, Weissleder R, Mueller PR
MR imaging of lymph nodes in patients with primary abdominal and pelvic malignancies using ultrasmall superparamagnetic iron oxide (Combidex).
Acad Radiol. 1998;5 Suppl 1:S167-9, discussion S183-4 - PMID: 9561072
1
Harisinghani MG, Saini S, Weissleder R, Halpern EF, Schima W, Rubin DL, Stillman AE, Sica GT, Small WC, Hahn PF
Differentiation of liver hemangiomas from metastases and hepatocellular carcinoma at MR imaging enhanced with blood-pool contrast agent Code-7227.
Radiology. 1997;202(3):687-91 - PMID: 9051017
1
|
